enGene Share Price

enGene Share Price

NASDAQ: ENGNW | Healthcare
$0.18
+$0.18 (--%) Last updated on 13 Nov, 2026 | 21:00 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

enGene Stock Performance

Open
$0.18
Prev. Close
N/A
Circuit Range
N/A
Day Range
$0.18 - $0.18
Year Range
$0.14 - $3.92
Volume
876
Average Traded
$0.18

enGene Share Price Chart

$0.18$0.18
L
Show Current Price
H

enGene Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$0.00
Return On Equity (TTM)
-56.61%
Profit Margin
N/A
Debt to Equity
0.11
Quarterly Earnings Growth YoY
14.20%

enGene Quarterly Profit & Loss

All figures in USD

ParticularsOct 2025Jan 2026Apr 2026Jul 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$37.88-$29.75-$30.23-$32.50
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A21.46%-1.61%-7.51%

enGene Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$55.14-$117.30
Net Profit MarginN/AN/A
Income ChangeN/A-112.73%

enGene Balance Sheet

All figures in USD Million

Particulars20252024
Non Current Assets20.0863.81
Current Assets201.39247.36
Total Assets221.47311.17
Non Current Liabilities21.7823.9
Current Liabilities31.9814.66
Total Liabilities53.7638.56
Shareholders' Equity167.71272.61

enGene Cash Flow

Annually

All figures in USD Million

Particulars20252024
Operating-99.24-48.28
Investing-25.14-125.95
Financing1.52265.72

About enGene

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

enGene Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.18
$0.18
-18.18%
Sep 2026
$0.19
$0.22
-24.66%
Aug 2026
$0.22
$0.29
-10.98%
Jul 2026
$0.26
$0.33
+36.67%
Jun 2026
$0.30
$0.24
+71.43%
May 2026
$2.03
$0.14
-94.44%
Mar 2026
$2.55
$2.52
-20.00%
Feb 2026
$3.00
$3.15
+11.70%
Jan 2026
$2.94
$2.82
-10.19%
Dec 2025
$2.62
$3.14
+14.60%
Nov 2025
$2.71
$2.74
+39.09%
Oct 2025
$0.79
$1.97
+181.43%

enGene Share Price FAQs